Pharmafile Logo

J‑Pharma Co., Ltd. and Uniphar Announce Advancement of Nanvuranlat into Phase 3 Clinical Development Following FDA Alignment and Initial Patient Enrollment

June 17, 2026 |  

- PMLiVE

Strategic partnership enables direct progression to Phase 3, bypassing additional Phase 2 study, as first patients are randomized in global trial 

TOKYO, Japan and DUBLIN, Ireland — [June 16, 2026] JPharma Co., Ltd., a clinical-stage biotechnology company focused on novel therapies targeting amino acid transporters, and Uniphar, a leading international healthcare services company, today jointly announced progress in the development of JPH203 (nanvuranlat), a novel LAT1 inhibitor for the treatment of second-line biliary tract cancer. Following alignment with the U.S. Food and Drug Administration (FDA), the program has advanced into Phase 3 clinical development and initial patients are now enrolled in the global study. 

Development History 

JPharma’s nanvuranlat program is rooted in pioneering work on LAT1, a transporter now widely recognized for its role in cancer biology. This scientific foundation traces back to Dr. Hitoshi Endou, founder of JPharma and Professor Emeritus of Kyorin University, who originally identified LAT1 as a therapeutic target. 

Building on Dr. Endou’s discovery, J-Pharma translated LAT1 biology into a therapeutic approach and discovered nanvuranlat, a first-in-class LAT1 inhibitor targeting amino acid transport mechanisms involved in tumor growth. 

In Phase 1 and Phase 2 studies conducted in Japan, JPharma demonstrated encouraging efficacy and safety signals in biliary tract cancer, supporting FDA agreement to advance to a global Phase 3 study. 

Through this progression, JPharma has advanced a discovery rooted in Japanese academic science into a global late-stage development program. 

Regulatory Strategy Enabling Phase 3 

Central to this milestone is the strategic partnership between JPharma and Uniphar Development, Uniphar’s regulatory and clinical development division, enabling FDA agreement on a Phase 3 study through a targeted regulatory engagement strategy, bypassing the need for an additional Phase 2 study.  

“Reaching Phase 3 with FDA alignment is a defining milestone for JPharma and, more importantly, for the patients with biliary tract cancer who urgently need new options,” says Max Yoshitake, President & CEO of JPharma. “Biliary tract cancer remains an area of significant unmet medical need worldwide, and we believe that bringing a new therapy to patients as quickly as possible carries major social significance. We are grateful for the close collaboration with Uniphar Development, which helped us translate our clinical data package into a clear regulatory strategy and global development path. We remain committed to working with Uniphar on the rigorous execution of the Phase 3 study and to exploring the potential of nanvuranlat for patients who may benefit from it.” 

First Patients Enrolled in Global Study 

Building on the regulatory foundation established through the partnership, JPharma has initiated its global Phase 3 study, with the first patients now successfully randomized. JPharma and Uniphar Development are jointly managing the Phase 3 study, with Uniphar Development also serving as JPharma’s U.S. agent with FDA. 

The program’s advancement into Phase 3 is helping to underpin investor confidence, contributing to JPharma’s successful completion of its initial public offering (IPO) in Japan in March 2026.  

“We are proud to stand alongside JPharma in announcing these achievements,” says Chuck Finn, PhD, Chief Scientific and Development Officer at Uniphar Development. “This collaboration demonstrates the power of an integrated regulatory and development approach. Uniphar’s extensive regulatory, oncology, and development expertise combined with JPharma’s scientific vision and development discipline, plus CEO Max Yoshitake’s global development experience, have been important factors in moving the program from data reassessment and FDA engagement to active Phase 3 enrollment. We are proud to continue supporting JPharma’s efforts to address unmet treatment needs for biliary tract cancer and bring meaningful new options to patients.” 

Uniphar Development continues to serve as JPharma’s U.S. regulatory and development partner, providing ongoing strategic support as the Phase 3 trial progresses. 

This content was provided by Uniphar

Company Details

 Latest Content from  Uniphar 

Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries

Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia,…

Uniphar Rebrands On Demand Business to Uniphar Global Sourcing, Strengthening Global Pharmaceutical Offering

Dublin, Ireland 16th July 2025 – Leading global healthcare services provider, Uniphar, has launched Uniphar | Global Sourcing, a new identity for its On Demand business that strengthens its position…

Uniphar Secures 10th Cell and Gene Therapy Project

[Dublin, April 17th 2025] Uniphar, a global leader in pharmaceutical and medtech solutions has announced the launch of its 10th cell and gene therapy (CGT) project. The milestone reinforces Uniphar’s…

Uniphar Expands Global Footprint with Three New Facilities in the USA, Netherlands and Ireland

[Dublin, 05 February 2025] Global partner to pharmaceutical and medtech manufacturers, Uniphar, is expanding its international presence with the launch of three new, state-of-the-art facilities, strategically positioned across key global…

Uniphar appoints industry leader, Isaac Batley, as Global Head of Scientific Communications

Isaac Batley, an experienced CEO with 35 years’ experience within healthcare and pharmaceutical communications, joins Uniphar to spearhead its medical communications division.

From molecule to market and beyond: Uniphar announces extended global commercialization platform

Healthcare services business, Uniphar, has developed its full-service offering that harnesses Uniphar’s 57 years in the industry delivering specialist services to more than 200 international clients across 180 countries.